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Aim: PNPLA3 I148M polymorphism (rs738409 C>G) is the most important 
and the best known polymorphism for nonalcoholic fatty liver disease 
(NAFLD). However, little is known about the effect of this polymorphism on 
NAFLD after liver transplantation (LT). We aimed to evaluate the association 
between this polymorphism and post-LT NAFLD. 
Methods: We designed a prospective case-control study. Among adult 
recipients who underwent LT between April 2014 and October 2015, those 
whose whole blood were preoperatively collected for genotyping in both 
recipients and coupled donors and those who have undergone protocol biopsy 
at post-LT 1 year were enrolled.
ii
Results: A total of 32 recipients were finally enrolled. Histologically proven 
steatosis (≥5%) were present in 28.1% of patients at a mean time of 12.7±2.0 
months after LT. Moderate and more steatosis (≥33%) was present in 9.4%. 
One year after LT, steatosis was present in 50.0% of homozygous recipients 
with rs738409-G allele. It was present in 27.3% of heterozygous recipients 
with rs738409-G allele, and in 9.1% (p=0.041) of recipients with rs738409-
CC. Genotype of donor was not significantly (p=0.647) associated with post-
LT NAFLD. When both recipient and coupled donor showed heterogeneous 
or homozygous genotype of rs738409-G allele, there was significantly more 
post-LT NAFLD compared to that in others (47.1% vs. 6.7%; p=0.018). In 
uni- and multi-variate analysis, only the presence of rs738409-G risk allele in 
both donor and recipient was a significant risk factor for post-LT NALFD 
(relative risk, 26.95; p=0.048).
Conclusions: PNPLA3 I148M polymorphism can significantly affects 
histologically proven NAFLD at post-LT 1 year.
--------------------------------------------------------------
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Nonalcoholic fatty liver disease (NAFLD) affects a substantial proportion of 
the general population in the world. It is the leading cause of chronic liver 
disease in developed countries. In the context of liver transplantation (LT), 
recipients are at increased risk of developing a number of metabolic 
syndromes such as diabetes, weight gain, hypertension, and hyperlipidemia. 
They are more predisposed to NAFLD when compared to the general 
population.1-4 However, NAFLD in liver transplant recipients is equivocal. 
Very little has been published regarding this condition with increasing 
numbers of liver transplant recipients.3, 5
The etiology of NALFD and its progression are caused by complex 
interplay between genetic factors and environmental factors.6 Recently, an 
independent genome-wide association study has identified a non-synonymous 
sequence variation (rs738409 C>G) encoding an isoleucine-to-methionine 
substitution at position 148 in adiponutrin/patatin-like phospholipase-3 
(PNPLA3) gene. It appears to be the strongest determinant of human 
steatosis.7-10
Liver transplant recipients are unique in being truly chimeric individuals. 
Both recipient and donor genotypes can potentially impact the phenotype.11
Therefore, PNPLA3 I148M polymorphism (rs738409 C>G) of donor and/or 
recipient might be significant risk factors for the development of 
histologically proven NAFLD after LT. The objective of this study were: 1) to 
evaluate the prevalence and distribution of PNPLA3 I148M polymorphism 
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(rs738409-G) in donors and recipients, 2) to evaluate the effect of rs738409-G 
of donor and recipient on NAFLD in recipients after the first year of LT, and 3) 
to determine peri-transplant risk factors including PNPLA3 I148M 
polymorphism related with post-LT NALFD in relatively early phase after LT.
Patients and Methods
This was a prospective case-control study. Adult recipients who underwent 
living donor LT between April 2014 and October 2015 in our institute were 
enrolled. Eligible patients were recipients who have preoperatively collected 
whole blood for sequencing of PNPLA3 (rs738409) genotype with coupled 
live donors under informed written consent. Among them, recipients who 
have undergone protocol biopsy at post-LT 1 year were finally enrolled in the 
present study.
In the present study, we excluded patients who underwent event-driven 
biopsy or those who were less than 18 years of age at the time of LT. Patients 
were also excluded if their clinical, histological, and/or biological features
were suggestive of recurrent liver diseases or the conditions related to hepatic 
fat accumulation after LT, such as 1) relapse of significant alcohol 
consumption, 2) HBs-Ag positivity, HCV-RNA positivity, and recurrent 
primary biliary cirrhosis, 3) biliary complication needed to intervention, and 4) 
using mTOR inhibitor or therapeutic dose of steroid.
A flow chart for the patient enrollment process is shown in Fig. 1. Among 
the 130 recipients who underwent living donor LT between April 2014 and 
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October 2015, a total of 91 recipients with coupled live donors underwent 
gene sequencing for PNPLA3 (rs738409) genotyping. Among them, a total of 
61 recipients were excluded because of no protocol biopsy at 1 year after LT 
(n=37), biliary complication (n=11), recurrent primary liver disease (5 cases 
of hepatitis C virus-RNA positivity, 3 hepatocellular carcinoma), use of 
mTOR inhibitor (n=1), follow-up loss (n=1), and expire during follow-up 
(n=1).
The study protocol conformed to the ethical guidelines of the 1975 
Declaration of Helsinki as reflected in a priori approval by the Institutional 
Review Board of Seoul Nation University Hospital.
Each recipient received induction with 20 mg of intravenous basiliximab 
within two hours before LT and on postoperative day 4. Basal 
immunosuppressive regimen was based on calcineurin inhibitor (tacrolimus), 
steroids, and Mycophenolate mofetil. Calcineurin inhibitor was started within 
5 days after LT. Tacrolimus doses were adjusted according to individual 
clinical need with respective target whole blood trough levels around 8-12 
ng/mL for the first month after LT, followed by 5-8 ng/mL thereafter. 
Mycophenolate mofetil dose was 1.0g daily (500mg twice a day) for most 
patients. Intravenous methylprednisolone 500 mg was given intra-operatively 
before portal perfusion. It was tapered from 200mg to 20mg within 6 days. 
Thereafter, oral prednisolone was continued at 20mg daily. It was tapered to 
0-5mg/day within about 6 months after LT.
  Outpatient follow-up were usually conducted once a week for the first 
month after discharge. It was gradually lengthened to every 3 or 4 months. 
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Additional visits were scheduled when clinically necessary. Complete 
laboratory examinations, including liver function tests and blood tacrolimus 
trough level were conducted at each follow-up.
As part of routine management, protocol liver biopsies were performed 
from postoperative days 7 to 14. They were performed afterwards when 
clinically necessary. Since August 2010, this practice was augmented with
additional biopsies at 1, 3, 5, and 10 years post-LT. In all cases, an informed 
consent was obtained from each patient before biopsy.
Genomic DNA was isolated from whole-blood samples prospectively 
collected before LT in recipients and their coupled live donors. Donor and 
recipient DNAs were analyzed for rs738409-G (NM_025225.2:c.444C>G 
NP_079501.2:p.Ile148Met) single nucleotide polymorphism in the PNPLA3 
gene based on Sanger Sequencing (BioFact Co. Daejeon, Korea). To genotype 
rs738409 single nucleotide polymorphism, the following primers were used: 
forward 5’-GCCAGCTGTG GCTACTCTGT-3’ and reverse ‘3-
TGTGGTGACC CAGTGTGACT C-5’. Polymerase chain reaction was 
carried out using the following conditions: denaturation at 95℃ for 3 minutes 
followed by 35 cycles of 20 seconds at 95℃, 40 seconds at 60℃, 30 seconds 
at 72℃, and a final extension at 72℃ for 5 minutes. The amplification size 
was 500bp. For quality control, genotyping was performed in duplicates. Both 
concordance rate and the overall success rate were 100%. 
Hepatic steatosis was defined as micro- and macro-vesicular lipid 
accumulations of 5% or more on biopsy specimens. The severity of steatosis 
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were evaluated using the steatosis grading and scoring system devised by the 
Pathology Committee of the Nonalcoholic Steatohepatitis Clinical Research 
Network: normal to minimal steatosis (<5%), mild steatosis (5-33%), 
moderate steatosis (>33-66%), marked or severe steatosis (>66%) 12-14. Sono-
guided fine needle aspiration liver biopsies was performed by specialized 
radiologists. The biopsy specimens were stained with hematoxylin-eosin and 
Masson trichrome stains. Pathologic reviews were performed by two 
hepatopathologists at the institution.
From medical records, past history such as alcohol or smoking, underlying
diseases such as diabetes or hypertension, laboratory data including liver 
function tests, and post-LT clinical course were obtained. Obesity was defined 
by BMI equal to or over 25.0kg/m2. Pre-existing donor graft steatosis was
evaluated at the time of initial organ procurement via liver biopsy. 
Hypertension was defined as blood pressure ≥130/85mmHg or by 
antihypertensive prescription, and diabetes was defined as fasting blood
glucose ≥126mg/dl, serum glucose ≥200mg/dl, or if patient was taking 
diabetes medication. 
Statistical analyses were performed using SPSS version 21.0. Continuous 
variables were compared with Student’s t test while categorical variables were 
compared using Pearson’s Chi-square test or Fisher’s exact test. Linear by 
linear association was used if a variable had more than two categories. For 
multivariate analysis, we used linear logistic regression analyses. All p-values 





The baseline characteristics of the 32 patients with coupled donors finally 
enrolled in this study are summarized in Table 1. The mean age of recipients 
was 55.25±8.89 months (range, 25-70 months). The mean age of donors was 
35.38±11.68 months (range, 19-58 months). Pre-existing steatosis was present 
in 40.7% of recipients and 21.9% of donors.
Prevalence and distribution of rs738409-G
The prevalence and distribution of rs738409-G are shown in Table 1. The 
genotype and allele frequencies of rs738409 polymorphism in this study fit 
with the Hardy-Weinberg equilibrium. The frequency of rs738409-G was 48.5% 
in recipients and 56.3% in donors (Table 1). There was no significantly 
difference in the frequency of rs738409-G allele in recipients and donors 
(P=0.479).
Prevalence and degree of steatosis after LT
Histologically proven steatosis (≥5%) was present in 28.1% (n=9) of patients 
at a mean period of 12.7±2.0 months between LT and biopsy (Table 2). Mild, 
moderate, and severe steatosis were present in 18.8% (n=6), 9.4% (n=3), and 
0.0% (n=0) of patients, respectively (Table 2). Additionally, other histological 
features were present in table 2.
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Proportion of post-LT steatosis according to the PNPLA3 (rs738409) 
genotype
The proportions of post-LT steatosis in recipients according to rs738409 
genotype in recipients and donors are shown in Fig. 2 (A) and Fig. 2 (B), 
respectively. At post-LT 1 year, there was a significant (P=0.041) difference in 
the prevalence of histologically proven steatosis according to the rs738409 
genotype in recipients. Steatosis was present in 9.1% of recipients with 
rs738409-CC homozygous genotype. It was present in 27.3% of recipients 
with rs738409-CG heterogeneous genotype and in 50.0% of recipients with 
rs738409-GG homozygous genotype (Fig. 2-A). According to rs738409 
genotype in donors, steatosis was present in 0.0% of recipients when their 
donors had rs738409-CC genotype. It was present in 50.0% of recipients 
when their donors had rs738409-CG and in 18.2% of recipients when their 
donors had rs738409-GG. Genotype of donor was not significantly (P=0.647) 
associated with post-LT NAFLD (Fig. 2-B). However, when both recipients 
and coupled donors showed heterogeneous or homozygous genotype of the 
rs738409-G risk allele, histologically proven steatosis at post-LT 1 year had 
significantly higher frequency compared to that in other groups (47.1% vs. 
6.7%; P=0.018). The presence of G allele in both donor and recipient was 
significantly (P=0.026) associated to post-LT steatosis (Fig. 2C).
Risk factors for steatosis at post-LT 1 year
Results of risk factor analysis for NAFLD are summarized in Table 3. In 
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univariate analysis, among the various clinical parameters, only genetic 
factors showed significant relation with steatosis at post-LT 1 year (Table 3 
(A)). Recipient PNPLA3 genotype (rs738409) was significantly different
between the group of steatosis and normal group (CC:CG:GG = 
43.5:34.8:21.7% vs. 11.1:33.3:55.6%, P=0.041). As previously described, 
genotype of donor was not significantly (P=0.647) associated with post-LT 
NAFLD. The presence of rs738409-G risk allele in both recipient and coupled 
donor was a significant factor for histologically proven post-LT NAFLD 
(88.9%; P=0.018). Factor of three and more rs738409-G alleles was also 
significant for histologically proven post-LT NAFLD (66.7%; P=0.049). 
Except genetic factors, other peri-transplant factors including age of recipient, 
pre-LT steatosis or pre-existing graft steatosis, pre-LT alcoholic liver cirrhosis, 
and obesity at the time of biopsy failed to show significant differences 
between the group of steatosis and normal group. 
In multivariate analysis with known potential risk factors for steatosis 
(recipient’s age ≥50 years, pre-LT steatosis, pre-existing graft steatosis, pre-LT 
alcoholic liver cirrhosis, obesity at the time of biopsy, weight gain after LT, 
and genotype of PNPLA3), only the presence of rs738409-G risk allele in 
both recipient and coupled donor (heterogeneous or homozygous) was 
significant independent risk factor for post-LT NALFD (relative risk, 26.95; 
95% confidence interval 1.04 to 701.40; P=0.048) (Table 3 (B)).
Discussion
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Single nucleotide polymorphism rs738409 in the PNPLA3 gene was first 
identified as a risk factor for steatosis in 2008 by the Dallas Heart Study.7
Rs738409-G is a well-established genetic risk factor for NAFLD in the 
general population.7-10, 15-18 However, NAFLD in liver transplant recipients is 
equivocal. Very little has been published regarding this condition.3-5, 19-21 To 
date, few studies have reported the association between PNPLA3 I148M 
polymorphism and post-LT NAFLD.
In a previous study, we have reported that histologically proven NAFLD is 
present in 27.1% of recipients at a mean period of 35.4 months between LT 
and biopsy.5 Even though the timing of biopsy was different, histologically 
proven NALFD was present with very similar prevalence (28.1%) in this 
study at a relatively early phase after LT (mean of 12.7 months). There was no 
NASH in our study population. That may be due to relatively early phase after 
LT. To the best of our knowledge, this is the first study about the association 
between PNPLA3 I148M polymorphism and histologically proven post-LT 
NAFLD. Liver biopsy remains the best method for diagnosing NALFD.22 In 
the present study, rs738409-G genotype of recipient was significantly 
(P=0.041) associated with NAFLD at one years after LT. However, genotype 
of donor was not significantly (P=0.647) associated with NAFLD at one year 
after LT. As previously described, steatosis was present in 50.0% of 
homozygous recipients with rs738409-G allele. It was present in 27.3% of 
heterozygous recipients and in 9.1% of recipients with rs738409-CC. When 
the rs738409-G alleles in both recipients and coupled donors were 
heterogeneous or homozygous, their combination was significantly associated 
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with NAFLD at one years after LT (relative risk, 26.95; 95% confidence 
interval 1.04 to 701.40; P=0.048). Regarding fibrosis, PNPLA3 
polymorphism has been known to be associated with liver fibrosis in various 
liver disease.10, 17, 23, 24 However, in the present study, there was no significant 
association between PNPLA3 polymorphism and fibrosis at 1 year after LT. 
In the present study, all recipients and donors are Asians (Korean). There 
are more homozygous recipients and donors with rs738409-G allele in this 
study population compared to the Western people. 9, 23, 25 The frequency of 
rs738409-G allele of PNPLA3 genotype has been reported from 22.6% to 
42.5% in the previous Western studies,9, 23, 25 which is less than that in this 
study population (48.5% in recipients and 56.3% in donors). There was no 
significant difference between recipients and donors in the present study 
(P=0.479).
Finkensteadt et al. have reported that liver transplant recipients who carry 
rs738409-GG in PNPLA3 are at increased risk for hepatic triglyceride 
accumulation, independent of the graft PNPLA3 genotype.20 In their study of 
95 recipients and coupled donors, at 5 years after LT, steatosis is present in 
63.2% of patients homozygous for the rs738409-G allele. It is present in 31.4% 
of heterozygous recipients and in 12.0% of rs738409-CC recipients 
(P=0.002).20 They have suggested that reduced PNPLA3 activity in 
extrahepatic tissues may be associated with hepatic fat accumulation in LT 
setting.20 They have reported that there is no association between PNPLA3 
genotype and steatosis at 1 year or 3 years after LT, which is different from 
our results. In the present study, for the first time, an association between 
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PNPLA3 and post-LT NALFD in recipients was found. This might be due to 
the fact that NALFD was diagnosed by unenhanced computed tomography in 
their retrospective study.20 Computed tomography is inaccurate and less 
sensitive diagnostic tool for hepatic steatosis, especially for mild degree of 
hepatic steatosis. Biopsy still remains the gold standard of diagnosis for 
NAFLD even though it is slightly invasive. The severity of hepatic steatosis 
can be accurately determined radiologically (unenhanced computed 
tomography or ultrasonography) only when there is moderate or severe fatty 
infiltration of the liver documented by a liver biopsy.26-28 We used histologic 
diagnosis to access post-LT steatosis. Histological diagnosis is a more 
accurate and more sensitive diagnostic tool for NAFLD compared to 
unenhanced computed tomography. Therefore, contrary to their suggestion, 
graft PNPLA3 genotype might be associated with the post-LT steatosis, 
especially when in combination with that of the recipient (Table 3). We 
suggested that reduced PNPLA3 activities in extrahepatic and hepatic tissues 
in combination might be associated with hepatic fat accumulation in early 
phase after LT. More studies are needed to determine the effect of PNPLA3 
genotype in recipients or donor on post-LT NAFLD. 
Recently, Liu et al. have reported that PNPLA3 I148M can affects de novo
NAFLD occurrence with a prominent interaction with obesity after studying 
65 long-term recipients with a survival exceeding 10 years.29 However, 
hepatic steatosis was diagnosed by inaccurate and subjective tool of 
ultrasound in their study.29 Even though fewer patients were used on the 
relationship between PNPLA3 I148M and NAFLD after LT in this study, our 
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results suggested that PNPLA3 I148M had somewhat significant effect on 
post-LT NAFLD.
Nongenetic factors previously identified as predictors of post-LT steatosis 
include pre-LT hypertension, diabetes mellitus, alcoholic cirrhosis, donor age, 
pre-LT graft steatosis, weight gain or obesity after LT, tacrolimus-based 
regimen, and increased post-LT triglyceride concentrations.3-5, 21, 30 Among 
them, pre-LT alcoholic cirrhosis (odds ratio 8.03, P=0.003), obesity at biopsy 
(odds ratio 3.87, P=0.001), and preexisting donor graft steatosis (odds ratio 
3.15, P=0.022) have been found to be significant risk factors for histologically 
proven NAFLD at a mean 35.4 months after LT.5 However, in the present 
study, genetic factor of PNPLA3 genotype was the only risk factor for 
NAFLD at 1 year after LT. The association between PNPLA3 genotype and 
post-LT NAFLD was independent of pre-LT alcoholic cirrhosis, age, 
preexisting donor graft steatosis, obesity after LT, or pre-LT steatosis.
It is well known that NAFLD can progress to non-alcoholic steatohepatitis, 
cirrhosis, or hepatocellular carcinoma,25, 31-34 and obesity and metabolic 
syndrome, even though somewhat controversial.31, 35, 36 NAFLD is an 
independent risk factor for cardiovascular disease and emerging data show 
that NAFLD plays important roles in the pathogenesis of chronic kidney 
disease.37-41 Recognizing post-LT NAFLD is important because it may 
significantly affect graft and patient survival by promoting fibrosis and 
cirrhosis and by related cardiovascular disease and chronic kidney disease.4, 37
NAFLD is modifiable through lifestyles such as body weight reduction. 
Therefore, healthy diet and physical activity are the cornerstones in the 
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treatment of NAFLD.42, 43 Shen et al. have suggested that, although PNPLA3 
rs738409-GG genotype confers a higher risk of NALFD, these patients are 
more sensitive to beneficial effects of lifestyle modification and should be 
encouraged to do so.44, 45 Since NAFLD was present in a considerable portion 
(28.1%) of patients in a relatively early phase (1 year) after LT, genetic factor 
might play a significant role. If we know the PNPLA3 genotype of both 
recipient and donor, we can predict the risk for post-LT NAFLD and actively 
recognize post-LT NAFLD through protocol biopsy so that we can prevent or 
treat it through lifestyle modification from an early phase after LT. These 
efforts can reduce post-LT NAFLD. They might improve long-term post-
transplant survival of recipients.
The present study had several limitations, especially in respect to relatively 
small number of patients in study cohort. The post-transplant course can be 
complex and heterogeneous in cases. This might not have been adequately 
adjusted for in the analysis. Even though we excluded other possible risks for 
secondary hepatic steatosis, there might be a selection bias in the process of 
identification of post-LT NAFLD. Nevertheless, the current study had several 
strengths. To the best of our knowledge, the present study was the first one 
that reported the association between PNPLA3 genotype and histologically 
proven NAFLD after LT. Even though a relatively small number of study 
population (n=32) was used in this study, the prevalence and distribution of 
PNPLA3 genotype in finally enrolled patients was similar to that in initially 
enrolled patients (n=91). A total of 37 patients who were excluded from this 
study because of no biopsy made their decision on whether to performed 
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protocol biopsy at 1 year after LT or not entirely by themselves (i.e., there was 
no intervention of researchers in the process of protocol biopsy). Therefore, 
even if the number of finally enrolled patients is increased in our study 
population, the results might be similar to that of the present study. In addition, 
this is the prospectively designed case control study. Therefore, we believe 
that this study could serve as a useful background for future studies in this 
field. We plan to continue this study and follow the study cohort with serial 
protocol biopsies at specific time points such as post-LT 3 years, 5 years, and 
10 years.
In conclusion, PNPLA3 I148M polymorphism of recipient alone or 
combined with coupled donor can significantly affect histologically proven 
NAFLD at post-LT 1 year. This finding supports the importance of PNPLA3 
genotype as a genetic risk factor for post-LT NAFLD, especially in relatively 
early phase after LT.
15
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Data are presented as the mean ± SD
Abbreviation: LT, Liver transplantation; BMI, Body mass index; HCC, 
hepatocellular carcinoma
24
TABLE 2. Histological Features of Nonalcoholic Fatty Liver Disease 
(NAFLD) in Recipients After 1 Year
NAFLD Cases (n = 32) Prevalence
Steatosis























































Recipient age at LT (year)

















































CC : CG : GG










CC or CG : GG
Donor PNPLA3 genotypes
CC : CG : GG
CC : CG or GG
CC or CG : GG
Recipient & donor genotype
G allele in both
























Donor obesity (BMI ≥25kg/m2)










































Data are presented as the mean ± standard deviations or numbers with 
percentages in parentheses unless otherwise indicated. * Timing at a mean 
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period of 12.7±2.0 months between LT and biopsy. #Physiologic dose in all 
cases.








Age ≥ 50 years
Pre-LT steatosis of recipient
Pre-LT alcoholic liver cirrhosis
Obesity (BMI ≥25kg/m2) at Biopsy
Pre-LT graft steatosis of donor
Weight gain after LT























Abbreviation: LT, liver transplantation; BMI, body mass index.
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Figure 1.
Flow chart showing the enrollment of patients for the study. 




Steatosis and PNPLA3 of recipients and donors. 
Proportion of histologically proven steatosis in recipients at post-transplant 1 
year, according to the PNPLA3 genotype of recipients (A), donors (B), and 










서론: PNPLA3 I148M polymorphism (rs738409 C>G)은 비알코올성
지방간질환의 가장 중요하고 잘 알려진 polymorphism이다. 그러나,
이 polymorphism이 간이식 후의 비알코올성 지방간질환에 미치는
영향에 관해서는 알려진 바가 거의 없다. 본 연구는 PNPLA3 I148M 
polymorphism과 간이식 후 비알코올성 지방간질환과의 연관성을
알아보고자 하였다.
방법: 본 연구는 전향적 환자-대조군 연구이다. 2014 년 4 월부터
2015 년 10 월까지 서울대학교병원에서 간이식을 받은 성인 환자들
중에서, 환자 및 그의 기증자 모두에서 genotyping 을 위해
전향적으로 모은 전혈이 있고 간이식 후 1 년에 시행된 프로토콜
조직검사를 받은 간이식 환자를 대상으로 하였다. 
결과: 총 32명의 간이식 환자가 최종 연구대상이 되었다. 이식 후
평균 12.7±2.0 개월에, 조직학적으로 증명된 steatosis (≥5%)는
28.1%의 환자에서 있었다. 중등도 이상(≥33%)의 steatosis는 9.4%였다.
이식 후 1년에, rs738409-G allele의 homozygous 이식환자의 50%에서  
steatosis가 있었다. rs738409-G allele의 heterozygous 이식환자의
27.3%와 rs738409-CC를 가진 이식환자의 9.1%에서 steatosis가
있었다(p = 0.041). 기증자의 genotype은 이식 후 비알코올성 지방간과
유의하게 관련되지 않았다(p = 0.647). 환자 및 그의 기증자 모두에서
rs738409-G allele의 heterogeneous 혹은 homozygous genoypte인 경우가
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간이식 후 비알코올성 지방간질환이 유의하게 많았다(47.1% vs. 6.7%; 
p = 0.018).  단변수 및 다변수분석 결과, 이식환자 및 그의 기증자
모두에서 rs738409-G risk allele을 보이는 것이 간이식 후 비알코올성
지방간질환의 유일하게 유의한 위험인자였다(상대위험비, 26.95; p =
0.048).
결론: PNPLA3 I148M polymorphism은 간이식 후 1년에 조직학적으로
증명된 비알코올성 지방간질환에 유의하게 영향을 미칠 수 있다.
주요어: 조직검사, 지방간, 유전자형, 간지방증, 이식
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